Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapulmonary PK of SPR994 in Healthy Volunteers
NCT04710407Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tebipenem in lower respiratory tract infection (LRTI) and bacterial pneumonia, sponsored by Spero Therapeutics. Primary endpoint: Plasma PK and lung penetration of SPR859 following multiple doses at Day 3. Started Dec 2020; status: completed.
02
Drugs
tebipenem
03
Conditions
lower respiratory tract infection (LRTI)bacterial pneumonia
Beyond the preview
Go deeper on NCT04710407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710407.